多囊卵巢综合征一线促排卵治疗:个体参与者数据Meta分析
该个体参与者数据Meta分析纳入20项随机对照试验共3962例多囊卵巢综合征不孕女性,比较来曲唑与枸橼酸氯米芬(CC)、CC联合二甲双胍与单用CC等一线促排卵方案。来曲唑较CC改善活产率(RR 1.43,95%CI 1.17-1.75)和临床妊娠率(RR 1.45,95%CI 1.23-1.70)并缩短受孕时间;CC联合二甲双胍可能改善临床妊娠率但活产率差异证据不足。
要点
- 来曲唑较CC改善活产率(RR 1.43)和临床妊娠率(RR 1.45),并缩短受孕时间(HR 1.72)。
- CC联合二甲双胍较单用CC可能改善临床妊娠率(RR 1.18),活产率差异证据不足(RR 1.08,95%CI 0.87-1.35)。
- 来曲唑疗效与基线血清总睾酮水平存在正向交互作用(交互RR 1.29)。
核心结论
- 在多囊卵巢综合征不孕女性中,来曲唑较CC改善活产率和临床妊娠率并缩短受孕时间,可作为首选一线治疗。
- CC联合二甲双胍较单用CC可能提高临床妊娠率并可能缩短受孕时间,但活产率差异证据不足。
- 来曲唑疗效受基线血清总睾酮水平影响,CC联合二甲双胍疗效受基线血清胰岛素水平影响。
研究设计与样本
- 个体参与者数据Meta分析,检索MEDLINE、EMBASE和Cochrane对照试验中心注册库至2018年12月20日。
- 纳入比较CC、二甲双胍、CC联合二甲双胍、来曲唑、促性腺激素和他莫昔芬相互之间或与安慰剂/无治疗比较的随机对照试验,排除治疗抵抗女性。
- 获得20项随机对照试验共3962例多囊卵巢综合征女性的个体参与者数据,主要结局为活产。
主要发现
- 来曲唑与CC比较:3项随机对照试验共1043例女性,活产率RR 1.43(95%CI 1.17-1.75,中等确定性证据)。
- 来曲唑与CC比较:6项随机对照试验共1284例女性,临床妊娠率RR 1.45(95%CI 1.23-1.70,中等确定性证据)。
- 来曲唑与CC比较:6项随机对照试验共1235例女性,受孕时间HR 1.72(95%CI 1.38-2.15,中等确定性证据)。
- CC联合二甲双胍与单用CC比较:8项随机对照试验共1039例女性,临床妊娠率RR 1.18(95%CI 1.00-1.39,低确定性证据)。
- CC联合二甲双胍与单用CC比较:5项随机对照试验共907例女性,活产率RR 1.08(95%CI 0.87-1.35,低确定性证据)。
关键数值与推荐
- 来曲唑与CC比较,基线血清总睾酮水平与活产治疗效应存在正向交互作用(交互RR 1.29,95%CI 1.01-1.65)。
- CC联合二甲双胍与单用CC比较,基线胰岛素水平与活产治疗效应存在正向交互作用(交互RR 1.03,95%CI 1.01-1.06)。
- CC联合二甲双胍与单用CC比较:7项随机对照试验共898例女性,受孕时间HR 1.25(95%CI 1.00-1.57,低确定性证据)。
临床怎么用
- 作者认为,来曲唑可作为多囊卵巢综合征不孕女性首选一线促排卵治疗。
- 作者认为,CC联合二甲双胍较单用CC可能提高临床妊娠率并可能缩短受孕时间,但活产率差异证据不足。
- 作者认为,治疗与基线总睾酮、胰岛素水平的交互作用为多囊卵巢综合征相关无排卵性不孕的个体化管理提供了进一步见解。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Polycystic ovary syndrome (PCOS) is the most frequent cause of anovulatory infertility. In women with PCOS, effective ovulation induction serves as an important first-line treatment for anovulatory infertility. Individual participant data (IPD) meta-analysis is considered as the gold standard for evidence synthesis which provides accurate assessments of outcomes from primary randomised controlled trials (RCTs) and allows additional analyses for time-to-event outcomes. It also facilitates treatment-covariate interaction analyses and therefore offers an opportunity for personalised medicine. OBJECTIVE AND RATIONALE: We aimed to evaluate the effectiveness of different ovulation induction agents, in particular letrozole alone and clomiphene citrate (CC) plus metformin, as compared to CC alone, as the first-line choice for ovulation induction in women with PCOS and infertility, and to explore interactions between treatment and participant-level baseline characteristics. SEARCH METHODS: We searched electronic databases including MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials up to 20 December 2018. We included RCTs comparing the following interventions with each other or placebo/no treatment in women with PCOS and infertility: CC, metformin, CC plus metformin, letrozole, gonadotrophin and tamoxifen. We excluded studies on treatment-resistant women. The primary outcome was live birth. We contacted the investigators of eligible RCTs to share the IPD and performed IPD meta-analyses. We assessed the risk of bias by using the Cochrane risk of bias tool for RCTs. OUTCOMES: IPD of 20 RCTs including 3962 women with PCOS were obtained. Six RCTs compared letrozole and CC in 1284 women. Compared with CC, letrozole improved live birth rates (3 RCTs, 1043 women, risk ratio [RR] 1.43, 95% confidence interval [CI] 1.17-1.75, moderate-certainty evidence) and clinical pregnancy rates (6 RCTs, 1284 women, RR 1.45, 95% CI 1.23-1.70, moderate-certainty evidence) and reduced time-to-pregnancy (6 RCTs, 1235 women, hazard ratio [HR] 1.72, 95% CI 1.38-2.15, moderate-certainty evidence). Meta-analyses of effect modifications showed a positive interaction between baseline serum total testosterone levels and treatment effects on live birth (interaction RR 1.29, 95% CI 1.01-1.65). Eight RCTs compared CC plus metformin to CC alone in 1039 women. Compared with CC alone, CC plus metformin might improve clinical pregnancy rates (8 RCTs, 1039 women, RR 1.18, 95% CI 1.00-1.39, low-certainty evidence) and might reduce time-to-pregnancy (7 RCTs, 898 women, HR 1.25, 95% CI 1.00-1.57, low-certainty evidence), but there was insufficient evidence of a difference on live birth rates (5 RCTs, 907 women, RR 1.08, 95% CI 0.87-1.35, low-certainty evidence). Meta-analyses of effect modifications showed a positive interaction between baseline insulin levels and treatment effects on live birth in the comparison between CC plus metformin and CC (interaction RR 1.03, 95% CI 1.01-1.06). WIDER IMPLICATIONS: In women with PCOS, letrozole improves live birth and clinical pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be recommended as the preferred first-line treatment for women with PCOS and infertility. CC plus metformin may increase clinical pregnancy and may reduce time-to-pregnancy compared to CC alone, while there is insufficient evidence of a difference on live birth. Treatment effects of letrozole are influenced by baseline serum levels of total testosterone, while those of CC plus metformin are affected by baseline serum levels of insulin. These interactions between treatments and biomarkers on hyperandrogenaemia and insulin resistance provide further insights into a personalised approach for the management of anovulatory infertility related to PCOS.
引用
- Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019. PMID: 31647106. doi:10.1093/humupd/dmz029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。